Brought to you by 
Nestle Health Science gets ex-US and Canadian rights to Seres' CDI and IBD compounds
06 Nov 2020
Executive Summary
Seres Therapeutics Inc. licensed Nestle Health Science SA exclusive rights to develop and commercialize outside the US and Canada candidates aimed at Clostridium difficile infection (Phase II SER109 and preclinical SER262) and inflammatory bowel disease, including ulcerative colitis (Phase I SER287) and Crohn’s (SER301--unknown phase).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Nestle Health Science gets ex-US and Canadian rights to Seres' CDI and IBD compounds
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice